On the morning of November 24th, key indices in the Hong Kong stock market collectively surged. Both the Hang Seng Index and the Hang Seng Tech Index at one point rose over 1%. The representative index focusing on the innovative drug industry—the Hang Seng Biotechnology Index—at one point gained over 2%. The largest ETF tracking this index, the Hang Seng Healthcare ETF (159892), followed the index higher, with 3SBio and Innovent Biologics leading the gains.

The Hang Seng Biotechnology Index was launched by Hang Seng Indexes Company in 2019 to reflect the overall performance of the biotechnology sector in the Hong Kong stock market. Compared to indices highly concentrated on innovative drugs, the Hang Seng Biotechnology Index also covers upstream CXO, enabling it to more accurately capture the performance of the entire innovative drug industry chain.

HKEX is set to launch Hang Seng Biotechnology Index futures, further optimizing its expanding derivatives ecosystem. This new futures contract will begin trading on November 28, 2025, providing investors with a precise risk management tool. The Hang Seng Biotechnology Index is also set to become the only index within the Hong Kong stock market's healthcare and medical sector to have index futures.